Taken together with previous findings on metformin, the accidental discovery on at least two independent occasions of diabetes drugs capable of promoting allosteric FBP1 inhibition suggests this enzyme is a highly promising target for rational drug discovery approaches to develop next‐generation type 2 diabetes drugs based on the highly efficacious properties of metformin and salicylate. The gene discussed is FBP1; the disease is type 2 diabetes mellitus.